Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: GlobeNewswire
SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi™, with expanded payer access anticipated to facilitate further growth in total prescription demand. “We are extremely pleased with the completion of this milestone for Emrosi™,” said Claude Maraoui, Co-Founder, P
Show less
Read more
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERMPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERMGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERMPR Newswire
- Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks [Yahoo! Finance]Yahoo! Finance
DERM
Earnings
- 3/25/26 - Beat
DERM
Analyst Actions
- 3/26/26 - HC Wainwright
DERM
Sec Filings
- 4/6/26 - Form SCHEDULE
- 3/26/26 - Form 10-K
- 3/25/26 - Form 8-K
- DERM's page on the SEC website